Alnylam European Patent Upheld by Opposition Board

The patent includes claims covering methods of silencing about 130 genes using siRNAs of up to 49 nucleotides in length and had been challenged by Merck subsidiary Sirna Therapeutics, according to Alnylam.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories